Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

3.74USD
8 Dec 2016
Change (% chg)

$-0.02 (-0.53%)
Prev Close
$3.76
Open
$3.70
Day's High
$3.78
Day's Low
$3.62
Volume
417,588
Avg. Vol
498,744
52-wk High
$16.64
52-wk Low
$2.86

CLDX.OQ

Chart for CLDX.OQ

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 3.13
Market Cap(Mil.): $380.70
Shares Outstanding(Mil.): 101.25
Dividend: --
Yield (%): --

Financials

  CLDX.OQ Industry Sector
P/E (TTM): -- 41.20 30.65
EPS (TTM): -1.30 -- --
ROI: -45.85 -0.59 15.23
ROE: -48.12 -1.31 16.56

BRIEF-Celldex reports Q3 loss per share $0.29

* Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 07 2016

BRIEF-Celldex updates on acquisition of Kolltan Pharmaceuticals

* Will acquire Kolltan in a stock-for-stock transaction, in which upfront payment represents an equity value of approximately $62.5 million

Nov 01 2016

BRIEF-Celldex appoints Elizabeth Crowley as chief product development officer

* Celldex appoints Elizabeth Crowley as chief product development officer Source text for Eikon: Further company coverage:

Aug 11 2016

BRIEF-Celldex Therapeutics opens enrollment in phase 1/2 study of CDX-014

* Enrollment has opened in phase 1/2 study of CDX-014 in advanced renal cell carcinoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 11 2016

Earnings vs. Estimates